Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) Begins Phase 3 Studies in Japan With Cempra’s Solithromycin
December 05, 2016 08:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at Two Upcoming Investor Conferences
November 09, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
FDA Advisory Committee Votes That Efficacy Results of Cempra’s Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia
November 04, 2016 22:40 ET
|
Cempra, Inc.
—FDA PDUFA dates December 27 & 28, 2016— CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing...
Cempra Stock Trading Halted Today; FDA Advisory Committee to Discuss Solithromycin
November 04, 2016 07:05 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in Japan
November 01, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update
October 27, 2016 16:15 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Third Quarter 2016 Financial Results
October 25, 2016 16:15 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Presents Analysis Showing Rates of Failure for Existing CABP Antibiotics From Claims Database at Academy of Managed Care Pharmacy Meeting
October 04, 2016 16:15 ET
|
Cempra, Inc.
—More than 20 percent of adult CABP patients failed initial antibiotic monotherapy, including approximately one of four elderly patients— —Average U.S. macrolide resistance to S. pneumoniae...
Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study
September 29, 2016 16:15 ET
|
Cempra, Inc.
— Pre/post treatment biopsies confirm mean NAS reduction of 1.3 points after 90 days of treatment with solithromycin — — All six patients showed ALT reductions after 90 days of treatment with...
Cempra to Present at Three Upcoming Investor Conferences
September 01, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...